Additionally, various lncRNAs discussed earlier, such as MIAT (52), LINC01132 (56), MIR155HG (91), PCED1B-AS1 (64), NEAT1 (49), can serve as potential combined treatment targets to enhance the effects of HCC immunotherapy (Figure 2D). Here, MIAT is linked to hepatocellular carcinoma.